54 related articles for article (PubMed ID: 22157552)
1. SEOM clinical guidelines for using molecular markers in clinical practice.
Arrazubi V; Pazo R; Isla D; Pérez Gracia JL
Clin Transl Oncol; 2011 Aug; 13(8):587-91. PubMed ID: 21821495
[TBL] [Abstract][Full Text] [Related]
2. Molecular Testing in Non-Small-Cell Lung Cancer: A Call to Action.
Sathiyapalan A; Ellis PM
JCO Oncol Pract; 2024 Jan; 20(1):7-9. PubMed ID: 38033274
[No Abstract] [Full Text] [Related]
3. Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer.
Shinde R; Cao X; Kothari S
J Manag Care Spec Pharm; 2016 Oct; 22(10):1194-203. PubMed ID: 27668568
[TBL] [Abstract][Full Text] [Related]
4. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.
Teixidó C; Karachaliou N; Peg V; Gimenez-Capitan A; Rosell R
Transl Lung Cancer Res; 2014 Apr; 3(2):70-4. PubMed ID: 25806283
[TBL] [Abstract][Full Text] [Related]
5. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.
Conde E; Suárez-Gauthier A; Benito A; Garrido P; García-Campelo R; Biscuola M; Paz-Ares L; Hardisson D; de Castro J; Camacho MC; Rodriguez-Abreu D; Abdulkader I; Ramirez J; Reguart N; Salido M; Pijuán L; Arriola E; Sanz J; Folgueras V; Villanueva N; Gómez-Román J; Hidalgo M; López-Ríos F
PLoS One; 2014; 9(9):e107200. PubMed ID: 25248157
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer.
Han XH; Zhang NN; Ma L; Lin DM; Hao XZ; Liu YT; Wang L; Liu P; Yuan Z; Li D; Lin H; Sun Y; Shi YK
Virchows Arch; 2013 Oct; 463(4):583-91. PubMed ID: 23955278
[TBL] [Abstract][Full Text] [Related]
7. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Dogan S; Shen R; Ang DC; Johnson ML; D'Angelo SP; Paik PK; Brzostowski EB; Riely GJ; Kris MG; Zakowski MF; Ladanyi M
Clin Cancer Res; 2012 Nov; 18(22):6169-77. PubMed ID: 23014527
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
Ou SH; Bartlett CH; Mino-Kenudson M; Cui J; Iafrate AJ
Oncologist; 2012; 17(11):1351-75. PubMed ID: 22989574
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
Leduc C; Besse B
Ann Oncol; 2014 Oct; 25(10):2092. PubMed ID: 25035277
[No Abstract] [Full Text] [Related]
11. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
Solomon BJ; Cappuzzo F; Felip E; Blackhall FH; Costa DB; Kim DW; Nakagawa K; Wu YL; Mekhail T; Paolini J; Tursi J; Usari T; Wilner KD; Selaru P; Mok TS
J Clin Oncol; 2016 Aug; 34(24):2858-65. PubMed ID: 27022118
[TBL] [Abstract][Full Text] [Related]
12. Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer.
Brosseau S; Gounant V; Choudat L; Pluvy J; Zalcman G; Khalil A
Diagn Interv Imaging; 2018 Apr; 99(4):267-268. PubMed ID: 29472032
[No Abstract] [Full Text] [Related]
13. Incorporation of crizotinib into the NCCN guidelines.
Riely GJ; Chaft JE; Ladanyi M; Kris MG
J Natl Compr Canc Netw; 2011 Dec; 9(12):1328-30. PubMed ID: 22157552
[No Abstract] [Full Text] [Related]
14. Crizotinib and testing for ALK.
Shaw AT; Solomon B; Kenudson MM
J Natl Compr Canc Netw; 2011 Dec; 9(12):1335-41. PubMed ID: 22157554
[TBL] [Abstract][Full Text] [Related]
15. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
